Prospects of Chimeric Antigen Receptor T-Cell Therapy in Myelofibrosis: From Immunopathogenesis to Therapeutic Strategies
Engineered immune cells designed to fight both cancer and scarring show theoretical promise for myelofibrosis, a disease currently without cure except transplant.
This review establishes the immunopathological rationale for CAR-T cell therapy in myelofibrosis, proposing dual targets for both clonal elimination and fibrotic microenvironment remodeling, including CD123, MPL, FAP, and TGF-β/CXCR4 signaling axes. The paper outlines a combinatorial framework integrating CAR-T with JAK inhibitors as a potential disease-modifying approach for a condition currently lacking curative options outside of transplant.
What the study was
- Study design
- Narrative review
- Population
- Myelofibrosis patients
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cancers (Basel)
Why it surfaced
CAR-T in MF is an emerging and relevant topic given the lack of curative options; review with no primary data limits score.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.